Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy
Source : https://www.sciencedirect.com/science/article/abs/pii/S2452318623000028?via=ihub
Chimeric antigen receptor T-cell (CAR-T) therapy has been proven very effective in treating . Ciltacabtagene autoleucel (cilta-cel), a second-generation CAR-T cell with double hematologic malignancies B cell maturation antigen (BCMA)...
Conclusions: Our results suggested that serum sBCMA level changes in response to the clinical status of MM patients after anti-BCMA CAR-T therapy. Furthermore, sBCMA may be a auxiliary biomarker for disease monitoring in MM patients after CAR-T therapy.
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36762851/
Ide-cel therapy significantly prolonged progression-free survival and improved response as compared with standard regimens in patients with triple-class-exposed relapsed and refractory multiple myeloma who had received two to four regimens...
Conclusions: Ide-cel therapy significantly prolonged progression-free survival and improved response as compared with standard regimens in patients with triple-class–exposed relapsed and refractory multiple myeloma who had received two to four regimens previously. The toxicity of ide-cel was consistent with previous reports.
Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36705644/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: Ide-cel was associated with significant survival improvements in terms of both LYs and QALYs in patients with progressive triple-class-exposed RRMM. The ICER for ide-cel was similar to that of other approved and reimbursed RRMM therapies.
Is t(11;14)(q13;q32) good or bad for newly diagnosed... : Chinese Medical Journal
Source : https://journals.lww.com/cmj/Fulltext/9900/Is_t_11_14__q13_q32__good_or_bad_for_newly.309.aspx
1 Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China 2 Peking University People's Hospital, Peking University Institute of Hematology, Cytogenetics Laboratory, Beijing Key Laboratory of Hematopoietic...
Conclusions: This single-center, retrospective study showed that patients harboring t(11;14) had comparable survival to patients without any high-risk cytogenetics. Gain/amp of 1q21 was an adverse prognostic risk factor for patients with t(11;14) myeloma, a finding that provides a better understanding of this particular type of myeloma.
Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma - International Journal of Hematology
Source : https://link.springer.com/article/10.1007/s12185-023-03538-6
Background In the phase 2 KarMMa trial, patients with relapsed/refractory multiple myeloma (RRMM) achieved deep and durable responses with idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor (CAR)...
Conclusions: Ide-cel yielded deep, durable responses with a tolerable and predictable safety profile in Japanese patients with RRMM. These results are similar to those of the non-Japanese population in KarMMa.